Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 6/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | HKDC1 | Q2TB90 | 4/20 | 0.74 |
| ▸ | HTT | P42858 | 4/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | MPI | P34949 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 5/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9904567 | 0.89 | MAPT (0.78) | HSP90AA1LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL17969781 | 0.89 | ALDH1A1 (0.78) | HSP90AA1LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL2489785 | 0.85 | MAPT (1.00) | HSP90AA1LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL7538581 | 0.83 | PPARG (0.72) | HSP90AA1LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL21470361 | 0.82 | ALDH1A1 (0.54) | HSP90AA1LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL8285456 | 0.80 | MAPT (1.00) | HSP90AA1LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL10751474 | 0.80 | MAPT (0.64) | HSP90AA1LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL8359086 | 0.76 | PPARG (0.63) | HSP90AA1LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL21470359 | 0.75 | L3MBTL1 (0.48) | HSP90AA1LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL9793702 | 0.75 | MAPT (0.61) | HSP90AA1LMNAMAPTNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-20120276121-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2012-11-01 | — | — | US | disclosed |
| US-20120276121-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2012-11-01 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | SCARB1, MSR1, HAVCR2 | HSP90AA1 90/4885LMNA 2485/4885MAPT 4202/4885 |
| US-20120276121-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | SCARB1, MSR1, HAVCR2 | HSP90AA1 90/4885LMNA 2485/4885MAPT 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.